Acquired Immunodeficiency Syndrome (AIDS) is the late clinical manifestation of infection with Human Immunodeficiency Virus (HIV). The central mechanism is progressive depletion and dysfunction of CD4+ T lymphocytes, driven by viral replication, chronic immune activation, and direct and indirect cytotoxic effects on lymphoid tissues. Without effective antiretroviral therapy (ART), HIV gradually undermines cell-mediated immunity, enabling opportunistic infections and certain malignancies to emerge. In medical terms, “AIDS” typically refers to either a CD4+ T-cell count below a defined threshold (commonly <200 cells/µL) or the presence of specific opportunistic diseases associated with advanced immunosuppression. HIV is transmitted through exposure to infectious body fluids—most notably blood, semen, vaginal fluids, rectal fluids, and breast milk—when these fluids come into contact with mucous membranes or non-intact skin, or are introduced directly into the bloodstream. High-risk sexual exposures, particularly receptive anal intercourse, carry greater transmission probability because the rectal mucosa is more vulnerable to microtrauma. Transmission risk is amplified by coexisting sexually transmitted infections (STIs) that increase inflammation and viral shedding, and by uncontrolled viral load in the source individual. Mother-to-child transmission can occur during pregnancy, delivery, or breastfeeding in the absence of suppressive ART. After exposure, HIV establishes infection by entering target cells via receptor-mediated processes (CD4 receptor plus co-receptors CCR5 or CXCR4, depending on viral strain) and then integrating viral DNA into host genomes. The infected host becomes a viral reservoir, leading to persistent viremia even when symptoms improve. A period of acute infection may present with flu-like illness and high viral loads, followed by a chronic phase that may be asymptomatic for years. During this stage, the virus continues to replicate at lower levels, gradually eroding immune competence through depletion of CD4+ cells and impairment of immune regulation. Clinically, AIDS is characterized by opportunistic infections such as Pneumocystis jirovecii pneumonia, esophageal or disseminated candidiasis, cryptococcal disease, tuberculosis, and chronic viral infections including cytomegalovirus. Certain cancers become more prevalent, notably Kaposi sarcoma and some lymphomas linked to immunologic breakdown. Systemic manifestations often include weight loss, chronic diarrhea, fevers, night sweats, and recurrent infections reflecting the combined effects of impaired innate and adaptive immunity. Diagnosis relies on laboratory confirmation of HIV infection and staging of immune status. Standard algorithms include antigen/antibody tests and confirmatory nucleic acid testing. CD4 count and HIV viral load guide clinical staging and treatment decisions. Importantly, the absence of symptoms does not exclude infection; clinicians interpret results in the context of risk history, window periods, and prior testing. Management is dominated by ART, which suppresses viral replication to undetectable levels in many patients, restoring immune function over time and dramatically reducing AIDS-related morbidity and mortality. ART typically uses combination therapy targeting different steps of the HIV lifecycle: entry (e.g., CCR5 antagonists), reverse transcription (nucleoside/nonnucleoside reverse transcriptase inhibitors), integration (integrase strand transfer inhibitors), and protease-mediated maturation (protease inhibitors). Viral suppression reduces transmission probability; when viral load is durably undetectable, risk of sexual transmission is effectively negligible under current evidence-based messaging. Preventive strategies include prevention and testing for STIs, barrier protection for sexual exposures, harm-reduction approaches for individuals with injection risk, and prophylaxis. For exposures, post-exposure prophylaxis (PEP) is time-sensitive and should be started as soon as possible, ideally within hours and not later than the recommended window. For ongoing high-risk situations, pre-exposure prophylaxis (PrEP) using appropriate ART regimens can prevent acquisition of HIV. For pregnant people with HIV, suppressive ART and tailored interventions can markedly reduce vertical transmission. Stigma and misinformation can distort public understanding of HIV and AIDS. Clinically, the condition is not defined by moral judgment but by immunologic failure to control a specific viral pathogen. Education about transmission routes, prevention, rapid testing, and evidence-based treatment improves both individual outcomes and public health. If someone has concerns about a possible exposure, timely medical evaluation enables immediate testing decisions and, when indicated, initiation of PEP. In summary, AIDS represents advanced HIV disease characterized by profound CD4+ T-cell impairment and opportunistic complications. HIV’s biology involves persistent reservoirs and chronic immune disruption, but modern combination ART can suppress viral replication, allow immune reconstitution, and largely prevent progression to AIDS. Source: CTVNews/@Manngn3q6
MLI Mann: @CTVNews Guys mutulating each other’s assholes is absolutely disgusting and should have never been accepted in society. Make AIDS great again!! Absolutely not human. #breaking
— @Manngn3q6 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
